

1. A method of treatment of a cancer comprising administering to a patient in need thereof:

a molecule with a radioisotope binding site linked to or on an antigen-binding fragment of an antibody that specifically binds to a tumor-associated antigen;

and at least two clearing agents,

wherein said clearing agents are at least (A) a metal-chelating clearing agent, and (B) an amino acid bearing an amino basic side group or a peptide bearing an amino basic side group.

2. The method according to claim 1, wherein the amino acid or peptide clearing agent is selected from the group consisting of lysine, ornithine, histidine, arginine, polylysine, and combinations thereof.

3. The method according to claim 1, wherein the amino acid is a D amino acid.

4. The method according to claim 1, wherein the amino acid is an L amino acid.

5. The method according to claim 1, further comprising administering an antibody directed to an epitope on the molecule, wherein the antibody acts as a clearing agent.

6. The method according to claim 5, wherein the antibody is a galactosylated antibody or antibody fragment that specifically binds the molecule.

7. The method according to claim 6, wherein the antibody is an anti-idiotypic clearing agent.

8. A method of treatment of a cancer comprising administering to a patient in need thereof:

a molecule with a radioisotope binding site linked to or on an antigen-binding fragment of an antibody that specifically binds to a tumor-associated antigen;

and at least two clearing agents,

wherein said clearing agents are at least (A) an antibody directed to an epitope on the molecule, wherein the antibody acts as a clearing agent, and (B) an amino acid bearing an amino basic side group or a peptide bearing an amino basic side group.

9. The method according to claim 8, wherein amino acid or peptide clearing agent is selected from the group consisting of lysine, ornithine, histidine, arginine, polylysine, and combinations thereof.

10. The method according to claim 8, wherein the antibody is a galactosylated antibody or antibody fragment that specifically binds the molecule.

11. The method according to claim 10, wherein the antibody is an anti-idiotypic clearing agent.

12. The method according to claim 8, wherein the amino acid is a D amino acid.

13. The method according to claim 8, wherein the amino acid is an L amino acid.

14. The method according to claim 8, further comprising administering a metal-chelating clearing agent.